Alpha cognition announces a $44 million exclusive licensing agreement for the development and commercialization of zunveyl (benzgalantamine), an fda-approved treatment for mild-to-moderate alzheimer's disease, in china

Vancouver, british columbia & dallas--(business wire)--alpha cognition, inc. (nasdaq: acog) (“aci” or the “company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and china medical system holdings limited (cms) (867.hk), a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability in the people's republic of china, today announced an exclusive licensing agreement for the.
ACOG Ratings Summary
ACOG Quant Ranking